Levodropropizine lozenges
Function and Efficacy
Not yet clear.
Ingredients
Levodropropizine. Chemical name: (-)-3-(4-phenyl-1-piperazinyl)-1,2-propanediol. Molecular weight: C13H20N2O2
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| LevodropropizineIngredients |
Not yet clear More |
99291-25-5 | 11 |
Appearance
This product is a white film-coated tablet, which appears white after removing the film coating.
Indication
No data yet
Usage and Dosage
Oral administration. Adults: 1 tablet (60 mg) each time, 3 times a day.
Adverse Reactions
Adverse reactions are rare, mainly manifested as gastrointestinal reactions, nausea, upper abdominal pain, indigestion, vomiting, diarrhea, central nervous system reactions, fatigue, dizziness, drowsiness, headache, palpitations, dry mouth, etc., occasionally visual impairment, rash, dyspnea are rare. Transient elevation of transaminase can be seen at high doses.
Precautions
1. It is contraindicated for those who are known or may be allergic to this type of drug; 2. It is contraindicated for those with excessive sputum or decreased mucociliary clearance function; 3. It is contraindicated for pregnant women and lactating women.
Special Population Medication
Precautions for children: Use with caution in children under 2 years old. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: There is no significant change in the pharmacokinetics of elderly patients, and there is no need to adjust the dosage or change the interval between medications.
Drug Interactions
1. Pharmacological studies on experimental animals have shown that this product is rapidly absorbed by the nervous system. 2. It also affects the hypoglycemic effect of insulin and digestive system drugs. 3. For particularly sensitive patients, caution should be exercised when taking inhibitory drugs at the same time. 4. Clinical studies have not found any adverse effects on the simultaneous use of other drugs for the treatment of bronchopneumonia.
Storage
seal.
Packaging Specification
30mg
Validity Period
24 months
Manufacturer
GUIZHOU-EAKAN Pharmaceutical Co., Ltd.
-
Founded in:
1993-10-28 -
Address:
No. 964, South Section of Huaxi Avenue, High-tech Industrial Development Zone, Guiyang City, Guizhou Province -
Tax NO.:
915201152144240368 -
Registered Funds:
42 million yuan -
Website:
-
Email: